The advent of selective BCR-ABL tyrosine kinase inhibitors revolutionized outcome in CML, and the knowledge about the precise molecular mechanisms of resistance, signal transduction, and disease biology is advancing [29]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.